Intelligence

Healthcare

New to The Street Schedules September 19 Broadcast Featuring BioVie, Acurx, Lantern Pharma and SafeSpace Global

Author:
FAQSIR News Desk
Last Updated:
Reading Time
3 min

New to The Street is scheduled to broadcast at 6:30 PM Eastern Time on September 19, 2026, with interviews featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), Lantern Pharma Inc. (Nasdaq:LTRN) and SafeSpace Global. The programme is set to air on Bloomberg Television across its United States, Latin America and Middle East and North Africa markets.

#BioVie interview to cover Long COVID trial results

BioVie President and CEO Cuong Do is scheduled to discuss the company’s Phase 2 ADDRESS-LC results for bezisterim in patients with Long COVID. The interview will address signals reported across measures involving fatigue, post-exertional malaise and cognitive symptoms.

Do is also expected to discuss the further clinical development of bezisterim and the design of a potential Phase 3 programme. BioVie is described as a clinical-stage biopharmaceutical company working on therapies for neurological, neurodegenerative and advanced liver diseases.

According to the supplied material, bezisterim is designed to target inflammation and insulin resistance-related biological processes believed to contribute to Long COVID and several neurodegenerative conditions. The material does not establish an efficacy conclusion or a regulatory outcome for the treatment.

#Acurx to present antibiotic development programme

Acurx Pharmaceuticals CEO David Luci is scheduled to discuss the company’s development of antibiotics for difficult-to-treat bacterial infections. The company’s lead candidate, ibezapolstat, is being developed as a potential treatment for Clostridioides difficile infection, also referred to as C. difficile or C. diff.

The interview is expected to include Acurx’s recent scientific work, its global intellectual-property portfolio and plans for advancing ibezapolstat towards Phase 3 clinical development.

#Lantern Pharma focuses on AI in oncology research

Lantern Pharma CEO Panna Sharma is scheduled to discuss the company’s use of artificial intelligence, machine learning and biomarker-led drug development in oncology research.

Lantern’s RADR® platform is designed to assist with identifying patient populations, finding potential new therapeutic indications and advancing precision oncology drug candidates. The supplied material does not state that these intended uses will deliver a particular clinical or commercial result.

#SafeSpace Global to discuss security platform

SafeSpace Global CEO Scott Boruff is scheduled to present the company’s artificial intelligence-powered security platform. The technology is designed for threat detection, emergency response and situational awareness in schools, senior-care facilities and other vulnerable environments.

The interview will cover the platform’s application to security operations, including earlier identification of risks and faster coordination of responses. The supplied material does not provide performance results or independent verification of the platform’s capabilities.

#Programme background and cautions

New to The Street describes itself as a sponsored and syndicated business television programme founded in 2009. Its stated distribution includes the United States, Latin America, the Middle East and North Africa, and Southeast Asia. The programme’s media operations also include digital content, social-media distribution and more than 6.3 million YouTube subscribers across New to The Street TV and NewsOut.

The programme states that some comments made during sponsored interviews may be forward-looking statements involving risks and uncertainties. Viewers are directed to consider each featured company’s public filings and official disclosures. New to The Street also states that its programming is not investment advice and should not be treated as a recommendation to purchase or sell any security.

#Key Takeaways

  • New to The Street is scheduled to air at 6:30 PM Eastern Time on September 19, 2026, across Bloomberg Television markets in the United States, Latin America and the Middle East and North Africa.
  • BioVie CEO Cuong Do is scheduled to discuss Phase 2 ADDRESS-LC results for bezisterim in patients with Long COVID.
  • Acurx CEO David Luci is expected to cover ibezapolstat and the company’s plans for potential Phase 3 clinical development.
  • Lantern Pharma and SafeSpace Global will discuss artificial intelligence applications in oncology research and security operations, respectively.
  • The programme cautions that statements in sponsored interviews may involve forward-looking risks and uncertainties.

Original source: Read original article

Frequently Asked Questions

New to The Street announces a broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), Lantern Pharma Inc. (Nasdaq:LTRN) and SafeSpace Global. The programme is scheduled to air tonight at 6:30 PM Eastern Time across Bloomberg Television's U.S., Latin America and Middle East and North Africa markets.
BioVie President and CEO Cuong Do is scheduled to discuss the company's recently announced Phase 2 ADDRESS-LC results evaluating bezisterim in patients suffering from Long COVID. The discussion includes what Do describes as encouraging signals across endpoints related to fatigue, post-exertional malaise and cognitive symptoms, as well as the continued clinical development of bezisterim and the design of a potential Phase 3 programme.
The source describes BioVie as a clinical-stage biopharmaceutical company developing therapies targeting neurological, neurodegenerative and advanced liver diseases. It says bezisterim is designed to address inflammation and insulin resistance-biological processes believed to contribute to Long COVID and several neurodegenerative conditions. The source does not provide a conclusion on the treatment's efficacy or regulatory outcome.
Acurx Pharmaceuticals CEO David Luci is scheduled to present the company's work developing a new class of antibiotics for difficult-to-treat bacterial infections. Its lead product candidate, ibezapolstat, is being developed as a potential treatment for Clostridioides difficile infection, also known as C. difficile or C. diff. The interview is also expected to cover recent scientific developments, the global intellectual-property portfolio and plans for advancing ibezapolstat towards Phase 3 clinical development.
Lantern Pharma CEO Panna Sharma is scheduled to discuss the use of artificial intelligence, machine learning and biomarker-driven drug development in oncology research. The source says the company's RADR® artificial-intelligence platform is designed to help identify patient populations, uncover new therapeutic indications and accelerate the development of precision oncology drug candidates. The source does not state that these intended uses will produce a particular clinical or commercial outcome.
SafeSpace Global CEO Scott Boruff is scheduled to present the company's artificial intelligence-powered security platform, which is designed to improve threat detection, emergency response and situational awareness across schools, senior-care facilities and other vulnerable environments. The interview is described as covering the combination of technology with security applications to identify risks earlier, coordinate responses faster and create safer spaces; the source does not provide performance results or independent verification.
The source describes New to The Street as a sponsored and syndicated business television programme and says certain statements made during sponsored interviews may constitute forward-looking statements involving risks and uncertainties. Viewers are directed to review each featured company's public filings and official disclosures. New to The Street states that it does not provide investment advice and that its programming should not be considered a recommendation to purchase or sell any security.